1. Crowdsourcing assessment of maternal blood multi-omics for predicting gestational age and preterm birth.
- Author
-
Tarca AL, Pataki BĂ, Romero R, Sirota M, Guan Y, Kutum R, Gomez-Lopez N, Done B, Bhatti G, Yu T, Andreoletti G, Chaiworapongsa T, Hassan SS, Hsu CD, Aghaeepour N, Stolovitzky G, Csabai I, and Costello JC
- Subjects
- Adult, Asymptomatic Diseases, Biomarkers blood, Blood Proteins classification, Blood Proteins metabolism, Cell-Free Nucleic Acids blood, Cell-Free Nucleic Acids classification, Crowdsourcing methods, Female, Humans, Infant, Newborn, Longitudinal Studies, Pre-Eclampsia blood, Pre-Eclampsia diagnosis, Pregnancy, Premature Birth blood, Premature Birth diagnosis, Proteomics methods, ROC Curve, Blood Proteins genetics, Cell-Free Nucleic Acids genetics, Gestational Age, Pre-Eclampsia genetics, Premature Birth genetics, Transcriptome
- Abstract
Identification of pregnancies at risk of preterm birth (PTB), the leading cause of newborn deaths, remains challenging given the syndromic nature of the disease. We report a longitudinal multi-omics study coupled with a DREAM challenge to develop predictive models of PTB. The findings indicate that whole-blood gene expression predicts ultrasound-based gestational ages in normal and complicated pregnancies (r = 0.83) and, using data collected before 37 weeks of gestation, also predicts the delivery date in both normal pregnancies (r = 0.86) and those with spontaneous preterm birth (r = 0.75). Based on samples collected before 33 weeks in asymptomatic women, our analysis suggests that expression changes preceding preterm prelabor rupture of the membranes are consistent across time points and cohorts and involve leukocyte-mediated immunity. Models built from plasma proteomic data predict spontaneous preterm delivery with intact membranes with higher accuracy and earlier in pregnancy than transcriptomic models (AUROC = 0.76 versus AUROC = 0.6 at 27-33 weeks of gestation)., Competing Interests: A.L.T., R.R., S.S.H., and T.C. are listed as co-inventors on the US 10,802,030 B2 patent, which involves the prediction of preterm birth using proteomics data. All of the other authors declare no competing interests., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF